Nkarta

NKTX Rare disease Lead: Phase 1 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-25

Catalyst timeline

Cabaletta rese-cel filing2026Cabaletta rese-cel filing, 2026, notable
NKX019 Ntrust-1 readout2H 2026NKX019 Ntrust-1 readout, 2H 2026, major
NKX019 Ntrust-2 readout2H 2026NKX019 Ntrust-2 readout, 2H 2026, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

NKX019

Cell Target: CD19

Lupus Nephritis Phase 1 Phase 1/2 trial NCT06557265
Primary Membranous Nephropathy Phase 1 Phase 1/2 trial NCT06557265
Systemic Sclerosis Phase 1 Phase 1/2 trial NCT06733935
Idiopathic Inflammatory Myopathy Phase 1 Phase 1/2 trial NCT06733935
ANCA-Associated Vasculitis Phase 1 Phase 1/2 trial
Systemic Lupus Erythematosus Phase 1 Phase 1/2 trial Columbia University Irving Medical Center NCT06518668
Myasthenia Gravis Phase 1 Phase 1/2 trial University of California, Irvine
Rheumatoid Arthritis Phase 1 Phase 1/2 trial NCT06733935

Technology platforms

CAR NK Platform

Modular NK cell engineering platform utilizing healthy donor-derived NK cells with proprietary technologies for expansion (NKSTIM cells), persistence (mbIL-15), CAR targeting/signaling, CRISPR-Cas9 genome editing, immune evasion, and cryopreservation. Enables off-the-shelf allogeneic CAR NK cell therapies; current focus on autoimmune diseases and prior oncology programs.

Discontinued (3)

NKX019 — undisclosed · deprioritized to direct primary resources to NKX019 for autoimmune diseases; enrollment closed 2023
NKX101 — undisclosed · deprioritized; oncology study closed patient enrollment in 2023
NKX070 — undisclosed · Company has deprioritized further development of NKX070; CRISPR opted out of continuing research of initial collaboration product

Biotech Distilled coverage (2)

2026-08-11 UPDATE: Nkarta (NKTX) - Below Cash, Burning Faster, Still Waiting 🔒 Paid
2026-05-26 Nkarta (NKTX) — Scientific Deep Dive for NKX019 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.